Latest Pharmaceutical Development News

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.

Argenica Therapeutics has reported positive Phase 2 trial results for ARG-007 in acute ischemic stroke patients, confirming safety and revealing a promising efficacy signal in a high-risk subgroup with slow collateral blood flow.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.